💊 Cipla Sees Strong Growth on Respiratory & US Business Momentum

Cipla continues to witness healthy growth driven by strong demand in respiratory therapies and improving performance in the US market. The company is benefiting from new product launches, robust domestic formulations business, and expanding global presence, supporting revenue growth and margins. Focus on specialty products and operational efficiency is further strengthening profitability. Management remains optimistic, backed by strong product pipeline, healthcare demand, and international market expansion. 📌 StockYard Take: Strong respiratory portfolio and global business growth position Cipla as a key pharma sector performer. #Cipla #PharmaStocks #Healthcare #USMarket #StockYardResearch